ARS Pharmaceuticals, Inc.

SPRY

ARS Pharmaceuticals, Inc.

SPRY

Insider Sentiment (TTM):

Last Purchase:2024-03-27Last Sale:2026-06-12Shares Purchased (TTM):0Shares Sold (TTM):216,563

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:90,661,140Shares Outstanding:99,296,408Institutional Ownership Pct.:91.30%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	8	24	41	60	52	40	51	40	37	56	71	61
Short Term Investments	136	177	204	229	189	236	263	165	182	168	157	181
Accounts Receivable Net Current	47	29	25	36	25	9	8	1	-	-	0	-
Inventory Net	-	-	31	-	-	7	11	1	-	-	0	0
Prepaid Expense And Other Assets Current	9	7	6	6	7	12	7	3	2	3	3	3
Assets Current	212	245	285	339	281	304	334	209	221	226	232	244
Inventory Noncurrent	19	23	23	14	13	12	5	-	-	-	0	-
Operating Lease Right Of Use Asset	-	-	-	1	2	0	0	0	0	0	0	0
Property Plant And Equipment Net	2	2	2	1	1	1	1	1	1	1	1	1
Intangible Assets Net Excluding Goodwill	14	14	14	15	13	7	7	8	-	-	0	-
Other Assets	3	3	3	3	3	3	3	0	0	1	1	3
Assets	249	288	328	373	313	327	351	218	222	228	233	249
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	60	48	38	50	44	27	23	17	7	3	2	11
Contract With Customer Liability Current	1	1	1	1	1	1	1	-	-	-	0	0
Operating Lease Liability Current	-	-	-	1	1	0	0	0	0	0	0	0
Other Liabilities Current	1	1	1	-	-	-	0	-	-	-	-	-
Liabilities Current	61	50	39	51	46	28	23	17	7	4	2	11
Long Term Debt	97	97	96	96	-	-	0	-	-	-	-	-
Contract With Customer Liability Noncurrent	1	1	1	1	1	1	2	-	-	-	0	0
Operating Lease Liability Noncurrent	-	-	-	1	1	-	0	0	0	0	0	0
Other Accrued Liabilities Noncurrent	3	4	5	4	1	-	0	-	-	-	-	-
Liabilities	237	226	213	225	121	98	94	17	7	4	2	11
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	430	417	409	401	394	386	380	374	369	366	362	362
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	-0	-0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-418	-355	-295	-253	-202	-157	-123	-173	-154	-142	-131	-124
Stockholders Equity	13	61	114	148	192	229	257	201	215	224	231	237
Liabilities And Stockholders Equity	249	288	328	373	313	327	351	218	222	228	233	249
Other Receivables Net Current	-	-	-	4	1	1	1	0	0	0	0	0
Related Party Deposit Liabilities	5	5	5	5	-	-	0	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	99	99	99	99	99	98	98	97	97	97	96	96
Shares Outstanding	99	99	99	99	99	98	98	97	97	97	96	96

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	15.29%	15.29%	-30.91%	-	-	-	-	-	-	-	-	-
2025	19.75%	36.53%	41.98%	-36.35%	-34.83%	-43.36%	11.82%	29.39%	12.50%	-8.29%	-5.41%	0.22%
2024	0.91%	-3.30%	24.77%	32.72%	46.42%	51.02%	-0.43%	-20.53%	-7.53%	-1.82%	-6.08%	1.26%
2023	-	-	-	-	-	-	44.31%	59.77%	83.24%	0.22%	-2.89%	-2.11%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.48	4.94	7.28	6.66	6.17	11.00	14.26	12.56	32.82	60.90	96.92	21.87
Quick Ratio	3.33	4.81	6.32	6.53	6.01	10.32	13.52	12.36	32.53	60.20	95.51	21.64
Working Capital	150.65M	195.62M	245.75M	287.99M	235.84M	276.24M	310.86M	192.17M	214.01M	222.53M	229.34M	233.29M
Leverage & Debt
Debt to Equity	18.94	3.69	1.87	1.52	0.63	0.43	0.37	0.08	0.03	0.02	0.01	0.05
Debt Ratio	0.95	0.79	0.65	0.60	0.39	0.30	0.27	0.08	0.03	0.02	0.01	0.05
Efficiency & Turnover
Asset Turnover TTM	0.42	0.32	0.25	0.48	0.42	0.35	0.31	0.01	0.00	0.00	0.00	0.00
Days Sales Outstanding TTM	112.32	70.00	72.59	47.58	81.64	34.96	33.47	109.87	-	-	-	-
Receivables Turnover TTM	3.25	5.21	5.03	7.67	4.47	10.44	10.91	3.32	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-2.17	-1.99	-1.74	-0.81	-0.49	-0.16	0.08	-0.51	-0.46	-0.52	-0.57	-0.64
Free Cash Flow Per Share TTM	-1.94	-1.77	-1.74	-0.46	-0.13	-0.21	0.13	-0.48	-0.46	-0.56	-0.63	-0.66
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	94.42%	94.33%	97.45%	-	-	-	-	-	-	-	-
Operating Profit Margin TTM	-184.96%	-204.49%	-212.92%	-63.59%	-52.82%	-27.87%	-3.46%	-2,356.15%	-11,347.20%	-619,990.00%	-225,066.67%	-242,456.67%
Net Profit Margin TTM	-184.24%	-200.00%	-203.25%	-56.06%	-42.74%	-16.11%	8.97%	-1,912.15%	-8,968.40%	-496,960.00%	-181,216.67%	-205,420.00%
Growth Metrics
Net Revenue Growth (1Y)	4.08%	1.92%	-5.46%	5,459.66%	22,367.80%	971,120.00%	297,063.33%	8,460.00%	128.31%	-98.51%	-97.72%	-97.72%
Net Income Growth (1Y)	348.66%	1,165.02%	-2,241.76%	63.00%	7.08%	-68.51%	-114.71%	-20.32%	-15.94%	17.23%	56.75%	-341.46%
EPS Growth (1Y)	344.36%	1,149.28%	-2,206.35%	60.07%	5.41%	-69.01%	-114.45%	-21.51%	-17.60%	14.48%	-34.22%	-177.70%
Valuation Metrics
P/E TTM	-3.69	-4.03	-6.70	-12.41	-35.75	-78.82	127.87	-28.65	-18.38	-19.84	-9.60	-5.86
P/B TTM	63.58	13.01	10.05	6.73	8.92	5.39	3.98	7.00	3.83	4.40	2.26	1.52
P/S TTM	6.80	8.06	13.63	6.96	15.28	12.70	11.47	547.89	1,648.01	98,609.19	17,392.67	12,042.65
Market Cap	795.49M	797.35M	1.15B	993.02M	1.72B	1.23B	1.02B	1.41B	824.00M	986.09M	521.78M	361.28M
Enterprise Value	884.01M	869.55M	1.20B	1.03B	1.66B	1.19B	971.86M	1.37B	787.38M	930.09M	450.81M	300.75M
Calculated Values
Free Cash Flow TTM	-192.49M	-175.40M	-171.29M	-45.27M	-12.63M	-21.06M	12.99M	-46.21M	-44.41M	-53.79M	-59.62M	-62.75M
Net Debt	88.51M	72.20M	55.06M	36.67M	-51.54M	-39.86M	-50.82M	-39.66M	-36.63M	-56.01M	-70.97M	-60.53M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-12Sale

Owner: Fitzpatrick, Alexander A

Title: Chief Legal Officer

Shares: 3,355

Price/Share: $10.00

Value: $33,550.00

Shares Owned: 90,910

Relationship: Officer

Ownership: Direct

2026-06-12Sale

Owner: Karas, Eric

Title: Chief Commercial Officer

Shares: 25,000

Price/Share: $10.00

Value: $250,000.00

Shares Owned: 12,176

Relationship: Officer

Ownership: Direct

2025-11-13Sale

Owner: Dorsey, Brian

Title: Chief Operating Officer

Shares: 21,828

Price/Share: $8.71

Value: $190,121.88

Shares Owned: 10,789

Relationship: Officer

Ownership: Direct

2025-11-12Sale

Owner: Chakma, Justin

Title: Chief Business Officer

Shares: 166,380

Price/Share: $8.88

Value: $1,477,454.40

Shares Owned: -

Relationship: Officer

Ownership: Direct

2025-08-21Sale

Owner: Lowenthal, Richard E

Title: PRESIDENT AND CEO

Shares: 50,000

Price/Share: $14.49

Value: $724,500.00

Shares Owned: 1,196,494

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-12	Fitzpatrick, Alexander A	Officer	Chief Legal Officer	Direct	Sale	3,355	10.00	$33,550.00	90,910	4
2026-06-12	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	25,000	10.00	$250,000.00	12,176	4
2025-11-13	Dorsey, Brian	Officer	Chief Operating Officer	Direct	Sale	21,828	8.71	$190,121.88	10,789	4
2025-11-12	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	166,380	8.88	$1,477,454.40	0	4
2025-08-21	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	50,000	14.49	$724,500.00	1,196,494	4
2025-08-21	Scott, Kathleen D.	Officer	Chief Financial Officer	Direct	Sale	12,500	15.00	$187,500.00	10,042	4
2025-08-20	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	37,656	14.09	$530,573.04	1,247,447	4
2025-07-01	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	15,000	16.99	$254,850.00	10,315	4
2025-06-27	Flynn, James E, Deerfield…	TenPercentOwner	-	Indirect	Sale	740,149	18.46	$13,663,150.54	4,887,254	4
2025-06-18	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	15,000	16.00	$240,000.00	7,696	4
2025-05-20	Fitzpatrick, Alexander A	Officer	Chief Legal Officer	Direct	Sale	102,969	14.10	$1,451,862.90	89,613	4
2025-05-20	Scott, Kathleen D.	Officer	Chief Financial Officer	Direct	Sale	50,000	14.10	$705,000.00	7,424	4
2025-05-20	Saunders, Brent L	Director	-	Direct	Sale	120,000	14.25	$1,710,000.00	0	4
2025-04-07	Shawver, Laura	Director	-	Direct	Sale	50,002	12.30	$615,024.60	210,346	4
2025-03-20	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	10,000	14.00	$140,000.00	7,696	4
2025-03-06	Shawver, Laura	Director	-	Direct	Sale	49,600	11.21	$556,016.00	210,346	4
2025-02-03	Shawver, Laura	Director	-	Direct	Sale	50,000	12.31	$615,500.00	210,346	4
2025-01-06	Shawver, Laura	Director	-	Direct	Sale	50,000	11.10	$555,000.00	210,346	4
2024-12-17	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	11.67	$1,167,000.00	1,098,499	4
2024-12-17	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	11.67	$1,167,000.00	1,098,499	4
2024-12-13	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	27,272	12.06	$328,900.32	136,380	4
2024-12-12	Dorsey, Brian	Officer	Chief Operating Officer	Direct	Sale	25,000	12.30	$307,500.00	6,024	4
2024-12-10	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	50,000	13.15	$657,500.00	136,380	4
2024-12-10	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	13.16	$1,316,000.00	1,148,499	4
2024-12-10	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	13.16	$1,316,000.00	1,148,499	4
2024-12-06	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	50,000	14.23	$711,500.00	136,380	4
2024-12-04	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	6,283	14.00	$87,962.00	5,693	4
2024-12-04	Shawver, Laura	Director	-	Direct	Sale	14,772	13.75	$203,115.00	210,346	4
2024-12-03	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	45,000	13.19	$593,550.00	136,380	4
2024-11-27	Chakma, Justin	Officer	Chief Business Officer	Direct	Sale	25,000	14.39	$359,750.00	136,380	4
2024-11-19	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	13.95	$1,395,000.00	1,198,499	4
2024-11-19	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	13.95	$1,395,000.00	1,198,499	4
2024-11-12	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	17.20	$1,720,000.00	1,248,499	4
2024-11-12	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	17.20	$1,720,000.00	1,248,499	4
2024-11-12	Deerfield, Private Design…	TenPercentOwner	-	Indirect	Sale	34,814	17.46	$607,852.44	5,257,328	4
2024-10-16	Scott, Kathleen D.	Officer	Chief Financial Officer	Direct	Sale	12,500	16.00	$200,000.00	4,949	4
2024-10-15	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	15.00	$1,500,000.00	1,298,499	4
2024-10-15	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	15.00	$1,500,000.00	1,298,499	4
2024-10-08	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	13.83	$1,383,000.00	1,346,494	4
2024-10-08	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	13.83	$1,383,000.00	1,346,494	4
2024-09-18	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	10,000	14.00	$140,000.00	5,693	4
2024-09-17	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	12.93	$1,293,000.00	1,398,499	4
2024-09-17	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	12.93	$1,293,000.00	1,398,499	4
2024-09-10	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	11.50	$1,150,000.00	1,396,494	4
2024-09-10	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	11.50	$1,150,000.00	1,396,494	4
2024-08-26	Orbimed, Capital Llc, Orb…	Director	-	Indirect	Sale	83,695	13.00	$1,088,035.00	0	4
2024-08-26	Thompson, Peter A.	Director	-	Indirect	Sale	83,695	13.00	$1,088,035.00	0	4
2024-08-23	Orbimed, Capital Llc, Orb…	Director	-	Indirect	Sale	69,500	13.03	$905,585.00	83,695	4
2024-08-22	Thompson, Peter A.	Director	-	Indirect	Sale	391,482	12.94	$5,065,777.08	153,195	4
2024-08-20	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	15.54	$1,554,000.00	1,497,447	4
2024-08-20	Scott, Kathleen D.	Officer	Chief Financial Officer	Direct	Sale	12,500	16.00	$200,000.00	13,199	4
2024-08-20	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	15.54	$1,554,000.00	1,497,447	4
2024-08-20	Dorsey, Brian	Officer	Chief Operating Officer	Direct	Sale	50,000	15.00	$750,000.00	6,024	4
2024-08-19	Karas, Eric	Officer	Chief Commercial Officer	Direct	Sale	10,000	14.00	$140,000.00	5,693	4
2024-08-13	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	12.27	$1,227,000.00	1,446,494	4
2024-08-13	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	12.27	$1,227,000.00	1,446,494	4
2024-08-13	Dorsey, Brian	Officer	Chief Operating Officer	Direct	Sale	30,000	13.00	$390,000.00	6,024	4
2024-07-16	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	11.40	$1,140,000.00	1,547,447	4
2024-07-16	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	11.40	$1,140,000.00	1,547,447	4
2024-07-09	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	9.62	$962,000.00	1,496,494	4
2024-07-09	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	9.62	$962,000.00	1,496,494	4
2024-06-12	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	95,862	9.14	$876,178.68	1,546,494	4
2024-06-12	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	95,862	9.14	$876,178.68	1,546,494	4
2024-05-16	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	89,096	9.06	$807,209.76	1,597,447	4
2024-05-16	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	89,096	9.06	$807,209.76	1,597,447	4
2024-05-07	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	9.34	$934,000.00	1,596,494	4
2024-05-07	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	9.34	$934,000.00	1,596,494	4
2024-04-16	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	9.28	$928,000.00	1,647,447	4
2024-04-16	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	9.28	$928,000.00	1,647,447	4
2024-04-09	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	100,000	9.28	$928,000.00	1,646,494	4
2024-04-09	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	100,000	9.28	$928,000.00	1,646,494	4
2024-03-27	Ra, Capital Management, L…	Director	-	Indirect	Purchase	505,954	9.79	$4,953,289.66	9,958,073	4
2024-03-25	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	95,267	9.12	$868,835.04	1,697,447	4
2024-03-25	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	95,267	9.12	$868,835.04	1,697,447	4
2024-03-21	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	472	9.00	$4,248.00	1,746,099	4
2024-03-21	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	472	9.00	$4,248.00	1,746,099	4
2024-03-15	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	96,756	9.14	$884,349.84	1,696,494	4
2024-03-15	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	96,756	9.14	$884,349.84	1,696,494	4
2024-02-29	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	3,782	9.02	$34,113.64	1,746,494	4
2024-02-29	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	3,782	9.02	$34,113.64	1,746,494	4
2024-02-28	Lowenthal, Richard E	Director,Officer,TenPercentOwner	PRESIDENT AND CEO	Indirect	Sale	98,778	9.02	$890,977.56	1,747,294	4
2024-02-28	Tanimoto, Sarina	Officer,TenPercentOwner	CHIEF MEDICAL OFFICER	Indirect	Sale	98,778	9.02	$890,977.56	1,747,294	4
2023-09-29	Fitzpatrick, Alexander A	Officer	Chief Legal Officer	Direct	Purchase	46,258	3.78	$174,855.24	89,227	4
2023-09-21	Ra, Capital Healthcare Fu…	Director	-	Indirect	Purchase	2,700,000	3.40	$9,180,000.00	8,556,774	4
2023-09-01	Shawver, Laura	Director	-	Direct	Sale	100,000	7.71	$771,000.00	210,346	4
2023-08-29	Ra, Capital Management, L…	Director	-	Indirect	Purchase	3,750,000	6.20	$23,250,000.00	5,856,774	4
2023-08-29	Thompson, Peter A.	Director	-	Indirect	Purchase	500,000	6.20	$3,100,000.00	8,019,187	4
2023-08-29	Orbimed, Capital Gp Vi Ll…	Director	-	Indirect	Purchase	500,000	6.20	$3,100,000.00	8,019,187	4
2023-08-04	Shawver, Laura	Director	-	Direct	Sale	18,897	7.06	$133,412.82	210,346	4
2023-08-02	Shawver, Laura	Director	-	Direct	Sale	36,281	7.09	$257,232.29	210,346	4
2023-07-07	Shawver, Laura	Director	-	Direct	Sale	8,858	6.36	$56,336.88	210,346	4
2023-07-06	Shawver, Laura	Director	-	Direct	Sale	33,510	6.34	$212,453.40	210,346	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

91.30%

Inst. Shares: 90,661,140

Shares Outstanding: 99,296,408

2025-12-31

88.56%

Inst. Shares: 87,288,535

Shares Outstanding: 98,566,481

2025-09-30

83.11%

Inst. Shares: 82,118,713

Shares Outstanding: 98,807,600

2025-06-30

84.32%

Inst. Shares: 82,940,368

Shares Outstanding: 98,361,771

2025-03-31

75.95%

Inst. Shares: 74,477,053

Shares Outstanding: 98,060,636

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	90,661,140	99,296,408	91.30%
2025-12-31	87,288,535	98,566,481	88.56%
2025-09-30	82,118,713	98,807,600	83.11%
2025-06-30	82,940,368	98,361,771	84.32%
2025-03-31	74,477,053	98,060,636	75.95%
2024-12-31	70,789,066	96,936,661	73.03%
2024-09-30	62,566,858	97,032,331	64.48%
2024-06-30	62,263,767	96,827,687	64.30%
2024-03-31	59,552,519	96,486,480	61.72%
2023-12-31	65,044,559	95,215,322	68.31%
2023-09-30	66,172,891	95,576,627	69.24%
2023-06-30	54,155,551	94,911,268	57.06%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ARS Pharmaceuticals, Inc. (SPRY) — SEC Financial Statements & Analysis

ARS Pharmaceuticals, Inc. (SPRY) is a pharmaceutical preparations company, incorporated in DE. ARS Pharmaceuticals, Inc. trades on Nasdaq as: SPRY. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ARS Pharmaceuticals, Inc. reported a 4.08% year-over-year revenue growth, a Gross Profit Margin of 94.42% (TTM), a Debt-to-Equity ratio of 18.94x, a Price-to-Sales (P/S) ratio of 6.80x (TTM), a Price-to-Book (P/B) ratio of 63.58x (TTM), at a market cap of $795.49M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 4.08%
Gross Profit Margin TTM: 94.42%
Debt To Equity: 18.94x
P/S TTM: 6.80x
P/B TTM: 63.58x
Market Cap: $795.49M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ARS Pharmaceuticals, Inc. in?

ARS Pharmaceuticals, Inc. (SPRY) operates in the Pharmaceutical Preparations industry.

What is SPRY's market cap?

ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $795.49M as of 2026-06-30.

What exchange does SPRY trade on?

ARS Pharmaceuticals, Inc. (SPRY) trades on the Nasdaq.

Where is ARS Pharmaceuticals, Inc. incorporated?

ARS Pharmaceuticals, Inc. is incorporated in DE.